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Abstract
Deposition of amyloid, derived from the polypeptide hormone islet amyloid polypeptide (IAPP; ‘amylin’) is the single most
typical islet alteration in type 2 diabetes. Islet amyloid was described as hyalinization already in 1901, but not until 1986 was it
understood that it is a polymerization product of a novel b-cell regulatory product. The subject of this focused review deals with
the pathogenesis and importance of the islet amyloid itself, not with the biological effect of the polypeptide. Similar to the
situation in Alzheimer’s disease, it has been argued that the amyloid may not be of importance since there is no strict correlation
between the degree of islet amyloid inﬁltration and the disease. However, it is hardly discussable that the amyloid is important
in subjects where islets have been destroyed by pronounced islet amyloid deposits. Even when there is less islet amyloid the
deposits are widely spread, and b-cells show ultrastructural signs of cell membrane destruction. It is suggested that
type 2 diabetes is heterogeneous and that in one major subtype aggregation of IAPP into amyloid ﬁbrils is determining
the progressive loss of b-cells. Interestingly, development of islet amyloid may be an important event in the loss of b-cell
function after islet transplantation into type 1 diabetic subjects.
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Introduction
It is now 25 years since we elucidated the nature of the
amyloid in the islets of Langerhans (1). Deposition of
amyloid is the most characteristic alteration in the
islets of Langerhans in type 2 diabetes and was
described already 110 years ago (2,3); it was for
long time named hyalinization of the islets.
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DOI: 10.3109/03009734.2011.573884A resemblance to amyloid was noted at an early date,
and when the nature of this substance was debated the
name ‘para-amyloid’ was sometimes used for deposits
like those in the islets (4). However, not until the
studies by Ehrlich and Ratner (5) was the material
accepted as a ‘real’ form of amyloid. It may be
mentioned that the discussion about inclusion criteria
for amyloid is still on-going (6). For a long time, the
interest for this alteration, which is quite characteristic
for type 2 diabetes, was generally low, but it was an
enigma mainly for pathologists who noticed the islet
alteration when examining autopsy specimens. The
low interest in amyloid among researchers in the
diabetes ﬁeld might have been due to the fact that
islet amyloid is missing in mouse and rat models of
diabetes. The reason for this absence became obvious
soon after our description of the nature of human (and
feline) islet amyloid (1,7). Another reason for the lack
of interest is that islet amyloid is not solely seen in
association with diabetes; it occurs also in non-
diabetic subjects but less commonly and to a lower
degree (8–10). The ﬁnding that islet amyloid is com-
posed by a previously unknown polypeptide hormone
immediately increased the interest in islet amyloid.
The elucidation of the islet amyloid nature
Gellerstedt, a professor of pathology at Uppsala
University, noted already in 1938 that the Congo
red staining property of islet amyloid was slightly
different from that of systemic amyloid (4). Also
histochemical studies indicated that the islet amyloid
was different (11,12). However, only an amino acid
sequence analysis could determine the nature of the
material. It was not an easy task to extract, purify, and
determine the nature of the main protein in islet
amyloid. In 1971 the two ﬁrst ﬁbril proteins from
systemic amyloidosis had been puriﬁed and deter-
mined by Edman degradation. One was found to be of
immunoglobulin light chain origin (13), while the
second turned out to be a previously unknown pro-
tein, now called AA (14). The third amyloid ﬁbril
protein to be characterized was calcitonin (or procal-
citonin) in the C-cell tumor thyroid medullary carci-
noma (15). In all these instances, the tissue material
serving for protein puriﬁcation was very rich in amy-
loid, making identiﬁcation of the main protein com-
paratively easy. Dealing with amyloid in the islets of
Langerhans was a completely different problem. This
amyloid is strictly limited to the around 1 million islets
which constitute about 1% of the total pancreatic
mass. A second problem was the unusual insolubility
of this amyloid (12). Previously studied amyloid pro-
teins had been puriﬁed after solubilization in guani-
dine hydrochloride, but islet amyloid turned out to
be completely insoluble in this solvent. After years
of trials, the solution to the problem came with a
b-cell tumor (insulinoma), rich in amyloid. With this
material a new approach was used, including solubi-
lization in concentrated formic acid, used for identi-
ﬁcation of the Ab protein (16), a new puriﬁcation
method with the aid of high-performance liquid chro-
matography and access to a new sensitive gas phase
sequenator. In this way, the nature of the protein was
ﬁnally elucidated (1). Surprisingly, it turned out to be
a novel b-cell protein, not related to insulin or its
precursor. It was initially named insulinoma (or islet)
amyloid peptide (IAP), which soon changed to islet
amyloid polypeptide (IAPP) since the abbreviation
IAP was already used. Further analyses, also of pro-
tein puriﬁed from amyloid derived from human and
cat islets (Figure 1), revealed a 37-amino acid residue
polypeptide belonging to the calcitonin gene-
related peptide (CGRP) family (7,17). Soon after-
wards, our ﬁndings were veriﬁed by another research
group (18). Parts of this group later named the pep-
tide ‘amylin’ (19). By immunohistochemistry (7,20),
immune electron microscopy (21,22), and later in-situ
hybridization (23) it was shown that IAPP is a product
of islet b-cells (24). IAPP is stored together with
insulin in the secretory vesicles. It is located to the
halo region where also proinsulin and C-peptide are
located. Although most of the circulating IAPP is
derived from islet b-cells, there is IAPP expression
in some gastrointestinal endocrine cells, in certain
peripheral ganglia, and in the brain (for review,
see (25)).
50 µm
Figure 1. Pancreatic section of case IsN13 with islets ﬁlled with
amyloid, stained with Congo red. This material was used to purify
the IAPP giving the ﬁrst amino acid sequence from human islet
origin.There are signs of pronounced autolysis, whichdid not affect
the quality of the puriﬁed peptide. There was also partial exocrine
atrophy which was helpful in that it made the amyloid more
concentrated.
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IAPP is a conserved molecule and is expressed in
mammals (26,27) (Figure 2), birds (28), ﬁshes
(29,30), and reptiles (Westermark and Westermark,
unpublished) although islet amyloid is seen only in a
limited number of species. As mentioned in the intro-
duction, islet amyloid does not appear in mouse or rat
islets. It is, however, a typical alteration in diabetes in
many non-human primate species (31,32)as well as in
cat species (33–35). Structural studies of islet amyloid
in several mammalian species revealed that IAPP is a
strongly conserved molecule but that there are con-
siderable species variations in a middle segment of the
peptide. It turned out that mouse and rat IAPP, which
are identical, carry three proline residues in the 20–
29 segment, where the human molecule has none and
the cat has one (26,36). While a synthetic peptide
corresponding to human IAPP 20–29 is extremely
ﬁbrillogenic in vitro, that corresponding to the rat/
mouse molecule is not (37). Consequently, it turned
out that the reason why islet amyloid is not found in
these rodents is simply that their IAPP is not amyloi-
dogenic. Parenthetically, it may be mentioned that
these species discrepancies have been utilized by a
pharmaceutical company to make a non-ﬁbrillogenic
IAPP variant, used for treatment of type 1 and
type 2 diabetes.
Amyloid in the degu: an interesting exception
There is a remarkable exception from the rule that
islet amyloid does not occur in species with apparently
non-ﬁbrillogenic IAPP, and that is the South Amer-
ican hystricomorphous rodent degu (Octodon degus).
This animal is prone to develop diabetes in captivity
(38). Degu IAPP has proline residues at positions
28 and 29 (39). In spite of this, islet amyloid is
common in elderly and diabetic animals (Figure 3).
Direct amino acid sequence analysis of puriﬁed degu
islet amyloid revealed surprisingly that the ﬁbril pro-
tein in this species is derived from insulin (40). In a
way, this ﬁnding closed the circle, since insulin was,
for natural reasons, believed to be the ﬁbril protein in
human islet amyloid (41) before IAPP was discov-
ered. Insulin is an amyloid protein also in human,
although an iatrogenic one; amyloid ‘tumors’ may
appear at the site of repeated insulin injections in
type 1 diabetic subjects (42,43).
Morphology of islet amyloid
Islet amyloid is restricted to the islet area and is not
found systemically or in other parts of the pancreas. In
human, islet amyloid is extracellular, and it has been
difﬁcult to ﬁnd certain intracellular amyloid. When
the deposits are small, amyloid can be seen as thin
layers between endocrine cells and capillaries and are
tapestrying the outside of the islet. When larger, the
deposits can form large masses completely remodel-
ing the islets (Figure 4). Amyloid can be visualized
with ordinary amyloid dyes such as Congo red and
shows the typical birefringence that can vary between
yellow and green (Figure 5), although erroneously
often referred to as ‘apple green’ (44). It should be
noted that the afﬁnity of this kind of amyloid for
Congo red often is weak or very weak, making it
easy to underestimate the amount of deposited mate-
rial or even to totally miss the amyloid. By deﬁnition,
islet amyloid consists of thin ﬁbrils, around 10 nm in
width, but with an undetermined length. Within
the deposits, the ﬁbrils are not organized, but close
50 µm
Figure 3. Pancreatic section of a degu (Octodon degus) with heavy
amyloid deposits at the islet periphery, stained with Congo red.
20 µm
Figure 2. Pancreatic section of a common shrew (Sorex araneus),
labeled with antibodies against IAPP. There is a strong reaction
with the b-cells, which constitute the majority of islet cells.
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ﬁbrils towards the cell membrane (24). Typically,
bundles of ﬁbrils run into deep pockets of b-cells,
seemingly penetrating the cell membrane (Figure 6).
A conspicuous feature of b-cells close to islet amyloid
is the distortion of the architecture of the outer part
of the cells and loss of an evident basement mem-
brane (24). The lack of intracellular amyloid in
b-cells of diabetic individuals does not necessarily
mean that aggregation of IAPP to ﬁbrils may not
take place here. In models with more rapidly devel-
oping islet amyloid, e.g. in human islets transplanted
into nude mice or in islets cultured in vitro, small
amyloid deposits develop within a few days or weeks
(45,46). This very ﬁrst amyloid is intracellular. We
have suggested that this ﬁrst amyloid leads to apo-
ptosis of the cell, leaving the amyloid, which is resis-
tant to degradation, extracellularly where it seeds
further amyloid formation from exocytosed IAPP
(46). Such an event might explain the deep pockets
into b-cells formed by the ﬁbrils when these are
elongated by addition of new IAPP molecules at
the cellular side (47).
The spreading of islet amyloid
An interesting phenomenon is that even very small
amyloid deposits are widely spread throughout an
individual islet (10), although other islets in the
neighbourhood are free. This might indicate that
the abnormality has affected all cells in the islet.
Amyloidogenesis is a nucleation-dependent phenom-
enon and does not start until a nucleus has formed
(48). However, when the ﬁrst ﬁbrils have assembled,
the process moves on rapidly as long as the peptide is
present above a critical concentration. The widely
spread amyloid in single islets may simply reﬂect
such events. Whether or not islets may communicate
so that amyloid can spread from one islet to another is
still an open question.
Why does IAPP form amyloid in
type 2 diabetes?
The pathogenesis of any localized form of amyloid is
not clear. Although most human proteins contain
segments that in theory are able to assemble into
amyloid ﬁbrils, most such parts are hidden in the
molecules and may be exposed only after cleavage
A
200 µm 200 µm
B
Figure 5. Section from the pancreas of a diabetic subject with severe islet inﬁltration of amyloid in all islets, visualized with Congo
red. The section in A is seen in ordinary light, while in B polarized light with crossed polars has been used. A bright yellow birefringence is
evident.
Figure 4. Human islet from a diabetic subject. Most of the islet has
been converted into amyloid, but there are still cords of cells, a
majority being b-cells, most probably dysfunctional. Congo red.
Bar: 50 mm.
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necessary for ﬁbrillogenesis since only full-length
molecules have been identiﬁed in the deposits,
although small amounts of propeptides can be dem-
onstrated by immunological techniques (50,51). Still,
aberration in the cleavage of pro-IAPP as an initial
step in amyloidogenesis cannot be ruled out (52). An
increased local concentration of the ﬁbrillogenic pro-
tein may be important. Over-production of insulin,
often seen in type 2 diabetes as a response to insulin
resistance, is associated with increased release also of
IAPP since these two b-cell products are normally
regulated in parallel (53). IAPP is a very ﬁbrillogenic
peptide in vitro, and its native conformation must be
controlled in vivo. Consequently, a further possible
factor in amyloidogenesis might be a dysregulation of
chaperones, normally hindering the strongly ﬁbrillo-
genic molecule IAPP from making amyloid. It is not
known exactly how IAPP is stored in granules and
which factors normally inhibit ﬁbril formation, but,
experimentally, insulin is a strong inhibitor (54–56).
Although insulin is mainly stored in crystalline form
in the granule core and IAPP in the halo region, it is
possible that there is enough insulin in the halo to
inhibit ﬁbril formation. Proinsulin, present in the
halo, is also an inhibitor (54). Finally, there may be
unknown inhibitors and promoters in IAPP amyloi-
dogenesis. Among additional components present in
all forms of amyloid and which may affect amyloido-
genesis are heparan sulfate (57) and serum amyloid
P-component (SAP) (58,59).
Is islet amyloid of any importance in
type 2 diabetes?
This question can be rephrased as to whether aggre-
gated IAPP in any form is pathogenically important
since there is evidence that not fully developed amy-
loid ﬁbrils but smaller, oligomeric assemblies exert
toxic effects on b-cells and thereby kill them (60).
It has even been suggested that the amyloid itself is
innocent and that its formation rather is a protection
mechanism by which the dangerous oligomeric spe-
cies are taken care of (61). In this paper, I will not
discuss oligomers more, and interested readers are
referred to a recent review (25). However, when
looking at a pancreatic section from a patient with
type 2 diabetes where almost all of the islets are
converted to amyloid (Figure 4), it is very difﬁcult
to believe that the amyloid itself is without
Figure 6. Electron micrograph showing a part of a b-cell from a diabetic subject. There are bundles of typical amyloid ﬁbrils which penetrate
deeply into the cells. Note that the cell is ﬁlled with characteristic insulin granules.
Amyloid in the islets of Langerhans 85importance. Both insulin (62) and IAPP(63) are
normally released in pulses. It is tempting to believe
that the tightly regulated pulses are disturbed by the
amyloid interposed between b-cells and capillaries
and most probably interfering with the cell membrane
function.
Another important issue is whether formation of
islet amyloid is a pathogenic event in the development
of type 2 diabetes or just participating in the ﬁnal
destruction of islets. This question cannot be
answered presently (64). A reason why islet amyloid
has been denied as a pathogenic mechanism in dia-
betogenesis is that islet amyloid does not occur in all
individuals with type 2 diabetes. Interestingly, in a
recent study on a baboon colony, islet amyloid
appeared before the development of diabetes, and
the amount of amyloid correlated well with the pro-
gression of the disease (65). It has not been possible to
demonstrate such a direct association in human.
What we call type 2 diabetes is heterogeneous in
human, and most probably several different mechan-
isms act in the pathogenesis. It is quite possible that,
in one major subgroup of individuals, aggregation of
IAPP and development of islet amyloid actually is
of major importance. It is also possible that deposi-
tion of islet amyloid acts in concert with other path-
ogenic mechanisms. This possibility will probably
not be answered until methods have been developed
by which amyloid deposits can be demonstrated
in vivo, e.g. by positron emission tomography
(PET), or until methods to prevent islet amyloid
formation or even to dissolve already formed ﬁbrils
have been introduced.
The b-cell mass in type 2 diabetes
For a long time there was no agreement concerning
the question whether there is a reduction in islet
volume and b-cell mass in type 2 diabetes. In early
studies, types 1 and 2 diabetes were usually not clearly
separated (66,67). Several later studies have shown a
modest reduction of the islet mass in type 2 diabetes
compared to age-matched controls, but there has
been a considerable overlap (68,69). This reduction
depends mainly on a smaller b-cell mass, shown in a
number of studies (64,70–72).
In one study we measured the total pancreatic
volume as well as islet volume in 12 subjects with
type 2 diabetes and 15 age-matched controls (69).
The total islet volume in non-diabetic subjects was
1.60 ± 0.16cm
3 (mean ± SEM) and in diabetic indi-
viduals 1.01 ± 0.12 cm
3 (P < 0.01). In another study
we found that the percentage of b-cells was signiﬁ-
cantly lower in islets of type 2 diabetic individuals
compared to non-diabetic controls (43.0% ± 22%
versus 59.2% ± 1.9%; P < 0.001) (70). If we assume
that the materials in these two studies, emerging from
the same department, are comparable, an estimate of
b-cell volume in type 2 diabetes and controls would be
0.43 ± 0.05 and 0.95 ± 0.09 cm
3, respectively. In
reality, the difference should be even greater since in
this calculation the volume taken up by amyloid has
not been taken into consideration. These data ﬁt well
with a ﬁnding that the b-cell area in diabetic subjects
was reduced only in amyloid-containing islets (64).
Even more intriguing was the signiﬁcant difference in
b-cell percentage between islets in non-diabetic
subjects with amyloid and those without any deposits
(70). While islets in those without any amyloid con-
tained 64.6% ± 1.4% b-cells, the percentage of b-cells
in islets in individuals with islet amyloid was 55.9% ±
2.5% (P < 0.01). This indicates that deposition of
islet amyloid is directly associated with b-cell loss and
not only a result of the diabetic state per se.
Limitations of islet volume determination in human
All islet volume determinations suffer from the lim-
itation that they have had to be performed on autopsy
material. That means that individuals with diabetes
usually have had their disease for several years, while it
would have been of greater interest to study the
pancreas very early in the diabetic state, or preferably
before diabetes had become established. This is pres-
ently impossible in humans until new methods have
been developed. Since the pancreas is very sensitive to
autolytic changes, obscuring histological details, it
should be pointed out that studies have to be per-
formed on material obtained well within 24 hours
after death, something that was possible in the
1970s but is completely impossible today, at least
in Sweden although it seems possible in some other
countries (72).
There are some good animal models which should
be relevant for human type 2 diabetes. Thus,
Howard showed that the diabetes which develops in
Macaca nigra resembles the human form (31). Islet
amyloid with loss of b-cells developed before overt
diabetes. A type 2-like diabetes can also be found in
elderly domestic cats (34,73). Baboons may also offer
a relevant model (see above). In addition, there are
transgenic mouse and rat models over-expressing
human IAPP in which diabetes associated with islet
amyloid develops (for review, see (25)).
Functional b-cell mass
Even inisletsﬁlled withamyloid,thereareanumberof
b-cells ﬁlled with secretory vesicles (24). These cells
are in direct contact with amyloid ﬁbrils and show
86 P. Westermarkmorphological signs of membrane damage and are
most probably not functioning in a normal way.
Therefore, the functional b-cell mass may be very
different from the total b-cell mass. A morphological
measurementofthetotalb-cellmassdoesnotgivetrue
functional mass.
Amyloid in transplanted human islets
Human islets isolated from organ donors may be
transplanted to diabetic recipients, particularly in
cases with diabetes which is difﬁcult to regulate
with the common regimens. Most commonly this is
done via an islet infusion into the portal vein. Initially,
many patients become independent of exogeneous
insulin injections, but most commonly the function
of the grafted islets deteriorates with time, and after a
few years most individuals need insulin treatment
(recently reviewed in (74)). Pioneered by Andersson
(75), human islets can be isolated and transplanted
into nude mice, some of which were made diabetic by
means of alloxan injections. We found that normal
human islets, transplanted under the kidney capsule
(45) or into the spleen or liver (76), rapidly develop
amyloid deposits. We therefore questioned whether
amyloid may form also in clinically transplanted islets
(77). Recently, we had the opportunity to study the
liver of one patient who had been transplanted 5 years
earlier and who died from a cardiac infarction.
Indeed, almost 50% of the studied islets contained
IAPP amyloid, often in a substantial amount (78).
This ﬁnding has recently been veriﬁed by studies of
additional cases (Westermark et al., unpublished).
Therefore, by transplantation of normal human
islets into type 1 diabetic individuals, type 2 diabetic
alterations are induced in these islets.
Conclusion
Porte pointed out two ﬁndings in type 2 diabetes,
providing clues to the pathogenesis: the relative
hyperproinsulinemia and the deposits of amyloid
in the islets (79). Hyperproinsulinemia would most
likely be associated with aberrant cleavage also of pro-
IAPP. There is evidence that the aberrant cleavage
product may start amyloid deposition by the forma-
tion of a nucleus (46,52). The amyloid formed may
cause b-cell apoptosis and dysfunction of remaining
cells. These mechanisms may also be important for
the loss of function of transplanted human islets.
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